Zydus Lifesciences Reports Rs 6,573.7 Cr Revenue in Q1 FY26, Net Profit Rises 3%
New Delhi: Zydus Lifesciences Limited has announced its unaudited consolidated financial results for the first quarter ended June 30, 2025, reporting steady growth across key geographies and product segments.
Revenue from operations stood at Rs 65,737 million, marking a 6% year-on-year (YoY) increase, while net profit rose 3% YoY to Rs 14,668 million. EBITDA for the quarter remained flat at Rs 20,885 million, with an EBITDA margin of 31.8%. Research and Development (R&D) investments during the period were Rs 4,856 million, constituting 7.4% of revenues.
The India geography business, comprising formulations and consumer wellness, contributed 37% to consolidated revenues, registering a 6% YoY growth. The formulations segment rose 8% YoY, driven by strong demand in cardiology, respiratory, anti-infectives, pain management, and oncology, with the chronic portfolio now accounting for 43.7% of the segment’s share. Consumer wellness grew 2% YoY, with organised trade saliency improving to 30.9%.
US formulations, the company’s largest contributor at 49% of revenues, grew 3% YoY to Rs 31,817 million, supported by three new product launches and six ANDA approvals, including two tentative. International markets formulations surged 37% YoY to Rs 7,265 million, while APIs registered an 11% YoY rise to Rs 1,575 million.
On the innovation front, the company initiated Phase II(b) clinical trials of Usnoflast, a novel oral NLRP3 inflammasome inhibitor for amyotrophic lateral sclerosis (ALS), which has received USFDA Fast Track and Orphan Drug Designations. It also secured DCGI marketing authorisations for Rituximab and Aflibercept biosimilars and commenced Phase III trials for a second antibody drug conjugate.
Operationally, Zydus received USFDA Establishment Inspection Reports for its Ankleshwar and Dabhasa API facilities. In the vaccines portfolio, Phase II trials for the Hepatitis E vaccine were completed, and Phase IV trials for rabies vaccine have been initiated.
Commenting on the results, Dr Sharvil Patel, Managing Director, said, “Our Q1 FY2026 performance reflects disciplined execution, with most key businesses meeting expectations. We remain firmly on track to achieve our FY2026 aspirations while upholding the highest compliance standards.”
